Brian Varnum - Armata Pharmaceuticals CEO Director
| ARMP Stock | USD 1.95 0.04 2.01% |
Insider
Brian Varnum is CEO Director of Armata Pharmaceuticals
| Age | 64 |
| Address | 5005 McConnell Avenue, Los Angeles, CA, United States, 90066 |
| Phone | 310 665 2928 |
| Web | https://www.armatapharma.com |
Brian Varnum Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Varnum against Armata Pharmaceuticals stock is an integral part of due diligence when investing in Armata Pharmaceuticals. Brian Varnum insider activity provides valuable insight into whether Armata Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Armata Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Armata Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Varnum over three months ago Acquisition by Brian Varnum of 298724 shares of Armata Pharmaceuticals at 3.15 subject to Rule 16b-3 |
Armata Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2457) % which means that it has lost $0.2457 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.3935) %, meaning that it created substantial loss on money invested by shareholders. Armata Pharmaceuticals' management efficiency ratios could be used to measure how well Armata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/18/2025, Return On Equity is likely to grow to 2.03, while Return On Tangible Assets are likely to drop (0.99). As of 02/18/2025, Total Current Liabilities is likely to grow to about 19.9 M. Also, Liabilities And Stockholders Equity is likely to grow to about 118.8 MSimilar Executives
| Found 9 records | INSIDER Age | ||
| Inbal BenjaminiElran | Biomx Inc | N/A | |
| Assaf Oron | Biomx Inc | 50 | |
| Thomas Schlumpberger | Anixa Biosciences | N/A | |
| Pamela Garzone | Anixa Biosciences | 70 | |
| Eran MD | Biomx Inc | N/A | |
| Inbar GahaliSass | Biomx Inc | N/A | |
| Jonathan MBA | Biomx Inc | 48 | |
| Pr Sorek | Biomx Inc | N/A | |
| Merav Bassan | Biomx Inc | 59 | |
Management Performance
| Return On Equity | -34.39 | ||||
| Return On Asset | -0.25 |
Armata Pharmaceuticals Leadership Team
Elected by the shareholders, the Armata Pharmaceuticals' board of directors comprises two types of representatives: Armata Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Armata. The board's role is to monitor Armata Pharmaceuticals' management team and ensure that shareholders' interests are well served. Armata Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Armata Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Martin, Advisor | ||
| Richard Rychlik, VP Controller | ||
| Todd MBA, Advisor | ||
| Pierre Kyme, Senior Development | ||
| Peter Hubbard, Vice Operations | ||
| MS MD, Chief Officer | ||
| Duane BA, VP Operations | ||
| Wenyuan Shi, CoFounder Scientist | ||
| David House, Senior Officer | ||
| Deborah MD, CEO Director | ||
| Brian Varnum, CEO Director | ||
| Bryan Kadotani, Vice Operations | ||
| Erin Butler, Principal Admin |
Armata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Armata Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -34.39 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (3.28) % | ||||
| Current Valuation | 193.74 M | ||||
| Shares Outstanding | 36.18 M | ||||
| Shares Owned By Insiders | 70.24 % | ||||
| Shares Owned By Institutions | 3.84 % | ||||
| Number Of Shares Shorted | 18.61 K | ||||
| Price To Earning | (1.65) X | ||||
| Price To Book | 4.06 X |
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.